本文選題：肝疾病 + 脂肪肝�。� 參考：《重慶醫(yī)學(xué)》2017年15期

【摘要】：目的系統(tǒng)評(píng)價(jià)利拉魯肽治療非酒精性脂肪肝病(NAFLD)的療效。方法計(jì)算機(jī)檢索Pubmed、EMBASE、the Cochrane library、中國(guó)知網(wǎng)、萬(wàn)方數(shù)據(jù)庫(kù)和中文科技期刊數(shù)據(jù)庫(kù),收集利拉魯肽治療NAFLD的隨機(jī)臨床對(duì)照研究(RCT),按排除和納入標(biāo)準(zhǔn)篩選文獻(xiàn)后,將納入文獻(xiàn)進(jìn)行質(zhì)量評(píng)價(jià)并提取相應(yīng)的數(shù)據(jù)后采用RevMan5.3軟件進(jìn)行Meta分析。結(jié)果共納入7個(gè)RCT共計(jì)500例非酒精性脂肪性肝病患者。使用利拉魯肽12~48周后,可顯著改善非酒精性脂肪性肝病患者的組織學(xué)特征,并降低患者血清中的丙氨酸氨基轉(zhuǎn)移酶水平[加權(quán)均數(shù)差(WMD)=-25.32,95%CI(-37.22,-13.41),P0.01]和天冬氨酸氨基轉(zhuǎn)移酶水平[WMD=-24.56,95%CI(-35.10,-14.03),P0.01]。但并不能降低患者的血清中三酰甘油水平[WMD=-14.38,95%CI(-48.95,-20.20),P=0.42]和總膽固醇水平[WMD=-15.55,95%CI(-36.20,-5.10),P=0.14]。結(jié)論利拉魯肽對(duì)NAFLD有一定的治療作用。
[Abstract]:Objective to evaluate the therapeutic effect of Lilaru peptide in the treatment of non-alcoholic fatty liver disease (NAF LDD). Methods A computerized search was conducted for Pubmedan EMBASEN the Cochrane library.China knowledge Network, Wanfang Database and Chinese Science and Technology Journal Database were used to collect the randomized clinical controlled study on the treatment of NAFLD with liraluP, and the literature was screened according to the exclusion and inclusion criteria. The quality of literature was evaluated and the corresponding data were extracted. Meta analysis was carried out with RevMan5.3 software. Results A total of 500 patients with non-alcoholic fatty liver disease were included in 7 RCT. After 48 weeks of treatment, the histopathological characteristics of patients with non-alcoholic fatty liver disease were significantly improved and the serum levels of alanine aminotransferase (alt) in patients with non-alcoholic fatty liver disease were significantly improved [WMD-25.32C95CI-37.22U -13.41 P0.01] and aspartate aminotransferase levels (WMD-24.56-95CI-35.10- 14.03P0.01). But it did not decrease the serum triacylglycerol level [WMD-14.38 / 95] and the total cholesterol level [WMD-15.595 / CI-36.20 / -5.10 / P0.14]. Conclusion Lilaru peptide has a certain therapeutic effect on NAFLD.
【作者單位】： 四川大學(xué)華西醫(yī)院臨床藥學(xué)部;四川大學(xué)臨床藥學(xué)與藥物不良反應(yīng)研究室;四川大學(xué)華西醫(yī)院老年科;四川大學(xué)分子醫(yī)學(xué)中心/生物治療國(guó)家重點(diǎn)實(shí)驗(yàn)室;
【分類號(hào)】：R575.5

【相似文獻(xiàn)】

相關(guān)期刊論文 前1條

1 金惠琳;趙紅燕;李媛紅;賈樹爾;馬琳娜;;利拉魯肽在2型糖尿病合并脂肪肝治療中的臨床觀察[J];哈爾濱醫(yī)藥;2014年04期

相關(guān)博士學(xué)位論文 前1條

1 白蓮;利拉魯肽對(duì)2型糖尿病非酒精性脂肪肝的作用及機(jī)制研究[D];天津醫(yī)科大學(xué);2014年

相關(guān)碩士學(xué)位論文 前6條

1 石志平;利拉魯肽降低2型糖尿病非酒精性脂肪肝大鼠肝臟磷酸化JNK的蛋白表達(dá)[D];河北醫(yī)科大學(xué);2015年

2 唐婷;利拉魯肽對(duì)體外誘導(dǎo)的非酒精性脂肪肝細(xì)胞內(nèi)質(zhì)網(wǎng)應(yīng)激的作用[D];河北醫(yī)科大學(xué);2016年

3 劉鑫;利拉魯肽對(duì)體外誘導(dǎo)的非酒精性脂肪肝細(xì)胞LC3Ⅱ、p62表達(dá)的影響[D];河北醫(yī)科大學(xué);2016年

4 范炳格;利拉魯肽對(duì)高糖環(huán)境下大鼠肝星狀細(xì)胞增殖的影響及與ERK信號(hào)通路關(guān)系研究[D];河北醫(yī)科大學(xué);2016年

5 高慧亭;利拉魯肽對(duì)非酒精性脂肪肝病的作用及JNK信號(hào)通路的影響[D];南方醫(yī)科大學(xué);2014年

6 李s，

本文編號(hào)：1936071